Africa Medical and Behavioral Sciences Organization
On 17th April 2026, Uganda marked a major milestone in HIV prevention at Lira Regional Referral Hospital with the official launch of Lenacapavir a groundbreaking injectable administered just twice a year to prevent HIV infection.
This moment was not only a national achievement but also a proud one for AMBSO.
AMBSO was honored to be represented at this landmark event by its Principal Investigators (PIs), who played a critical role in the clinical trials of Lenacapavir.
Through their dedication, expertise, and commitment to research excellence, these PIs contributed to the scientific evidence that has made this innovation possible.
Their involvement reflects AMBSO’s ongoing commitment to:
For many individuals, daily oral PrEP has been effective but challenging to maintain. The introduction of Lenacapavir offers a new path one that is:
The presence of AMBSO’s research team at Lira Regional Referral Hospital symbolized more than participation it represented years of research, collaboration, and commitment to public health.
As Uganda continues to strengthen its HIV prevention strategies, AMBSO remains proud to contribute to innovations that bring us closer to an HIV free generation.
With the rollout of Lenacapavir, the future of HIV prevention is becoming more accessible and sustainable.
AMBSO will continue to:
Together, we are shaping a healthier future.
